Effect of a single dose of tobramycin on systemic inflammatory response-induced acute kidney injury in a 6-hour porcine model

Critical Care Medicine

Volumn 37, Issue 10, 2009, Pages 2782-2790

  Lipcsey, Miklós ^a   Carlsson, Markus ^e   Larsson, Anders ^b   Algotsson, Lars ^a   Eriksson, Mats ^a   Lukinius, Agneta ^c   Sjölin, Jan ^d  

^a LUND UNIVERSITY   (Sweden)

^b Section of Clinical Chemistry

^c Department of Genetics and Pathology ^*

^d UPPSALA UNIVERSITY   (Sweden)

^e Eskilstuna County Hospital   (Sweden)

Author keywords

Aminoglycosides; Animal model; Endotoxic shock; Kidney failure; Sepsis; Swine

Indexed keywords

CEFUROXIME; CYSTATIN C; ENDOTOXIN; N ACETYL BETA GLUCOSAMINIDASE; SODIUM CHLORIDE; TOBRAMYCIN; UREA;

ACUTE KIDNEY FAILURE; ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BOLUS INJECTION; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; FEMALE; KIDNEY FUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPSIS; SINGLE DRUG DOSE; SWINE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UREA BLOOD LEVEL; URINE VOLUME;

EID: 70349668735     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181a988f8     Document Type: Article

References (46)

1. Kumar A, Roberts D, Wood KE, et al: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-1596
2. Dellinger RP, Carlet JM, Masur H, et al: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873 (Pubitemid 38344143)
3. Goscinski G, Lundholm M, Odenholt I, et al: Variation in the propensity to release endotoxin after cefuroxime exposure in different gram-negative bacteria: uniform and dosedependent reduction by the addition of tobramycin. Scand J Infect Dis 2003; 35:40-46
4. Vogelman B, Craig WA: Kinetics of antimicrobial activity. J Pediatr 1986; 108:835-840
5. Eliopoulos GM, Moellering RC: Antimicrobial combinations. In: Antibiotics in Laboratory Medicine. Baltimore, Lippincott Williams & Wilkins, 1996, pp 330-383
6. Paul M, Benuri-Silbiger I, Soares-Weiser K, et al: Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004; 328:668
7. Pannu N, Nadim MK: An overview of druginduced acute kidney injury. Crit Care Med 2008; 36(4 Suppl):S216-S223
8. Denamur S, Van Bambeke F, Mingeot- Leclercq MP, et al: Apoptosis induced by aminoglycosides in LLC-PK1 cells: Comparative study of neomycin, gentamicin, amikacin, and isepamicin using electroporation. Antimicrob Agents Chemother 2008; 52: 2236-2238
9. Zager RA: Gentamicin nephrotoxicity in the setting of acute renal hypoperfusion. Am J Physiol 1988; 254:F574-F581
10. Zager RA, Prior RB: Gentamicin and gramnegative bacteremia. A synergism for the development of experimental nephrotoxic acute renal failure. J Clin Invest 1986; 78: 196-204
11. Kohlhepp SJ, Hou L, Gilbert DN: Pig kidney (LLC-PK1) cell membrane fluidity during exposure to gentamicin or tobramycin. Antimicrob Agents Chemother 1994; 38:2169-2171
12. Williams PD, Holohan PD, Ross CR: Gentamicin nephrotoxicity. I. Acute biochemical correlates in rats. Toxicol Appl Pharmacol 1981; 61:234-242
13. Vera-Roman J, Krishnakantha TP, Cuppage FE: Gentamicin nephrotoxicity in rats. I. Acute biochemical and ultrastructural effects. Lab Invest 1975; 33:412-417
14. Schrier RW, Wang W: Acute renal failure and sepsis. N Engl J Med 2004; 351:159-169
15. Wan L, Bagshaw SM, Langenberg C, et al: Pathophysiology of septic acute kidney injury: What do we really know? Crit Care Med 2008; 36(4 Suppl):S198-S203
16. Buijk SE, Mouton JW, Gyssens IC, et al: Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 2002; 28:936-942
17. Laczika K, Staudinger T, Hollenstein U, et al: Renal tolerability of four different once-daily dose regimen of netilmicin in critical care patients. Wien Klin Wochenschr 1997; 109: 840-844
18. Lipcsey M, Larsson A, Eriksson MB, et al: Inflammatory, coagulatory and circulatory responses to logarithmic increases in the endotoxin dose in the anaesthetised pig. J Endotox Res 2006; 12:99-112
19. Bersten AD, Soni N, Oh TE: Physiological equations. In: Oh's Intensive Care Manual. Fifth Edition. Bersten AD, Soni N, Oh TE (Eds). Edinburgh, Butterworth-Heinemann, 2003, pp 1113-1115
20. Lukinius A, Jansson L, Korsgren O: Ultrastructural evidence for blood microvessels devoid of an endothelial cell lining in transplanted pancreatic islets. Am J Pathol 1995; 146:429-435
21. Foord RD: Cefuroxime: Human pharmacokinetics. Antimicrob Agents Chemother 1976; 9:741-747
22. Verhagen CA, Mattie H, Van Strijen E: The renal clearance of cefuroxime and ceftazidime and the effect of probenecid on their tubular excretion. Br J Clin Pharmacol 1994; 37:193-197
23. Alexander C, Rietschel ET: Bacterial lipopolysaccharides and innate immunity. J Endotox Res 2001; 7:167-202
24. Pridmore AC, Wyllie DH, Abdillahi F, et al: A lipopolysaccharide- deficient mutant of Neisseria meningitidis elicits attenuated cytokine release by human macrophages and signals via toll-like receptor (TLR) 2 but not via TLR4/MD2. J Infect Dis 2001; 183:89-96
25. Knotek M, Rogachev B, Wang W, et al: Endotoxemic renal failure in mice: Role of tumor necrosis factor independent of inducible nitric oxide synthase. Kidney Int 2001; 59: 2243-2249
26. Lipcsey M, Larsson A, Eriksson MB, et al: Effect of the administration rate on the biological responses to a fixed dose of endotoxin in the anesthetized pig. Shock 2008; 29: 173-180
27. Mingeot-Leclercq MP, Tulkens PM: Aminoglycosides: Nephrotoxicity. Antimicrob Agents Chemother 1999; 43:1003-1012
28. Hori R, Yamamoto K, Saito H, et al: Effect of aminoglycoside antibiotics on cellular functions of kidney epithelial cell line (LLC-PK1): A model system for aminoglycoside nephrotoxicity. J Pharmacol Exp Ther 1984; 230: 724-728
29. Takamoto K, Kawada M, Ikeda D, et al: Apolipoprotein E3 (apoE3) safeguards pig proximal tubular LLC-PK1 cells against reduction in SGLT1 activity induced by gentamicin C. Biochim Biophys Acta 2005; 1722:247-253
30. Klahr S, Miller SB: Acute oliguria. N Engl J Med 1998; 338:671-675
31. Bosomworth MP, Aparicio SR, Hay AW: Urine N-acetyl-beta-D- glucosaminidase-A marker of tubular damage? Nephrol Dial Transplant 1999; 14:620-626
32. Etherington C, Bosomworth M, Clifton I, et al: Measurement of urinary N-acetyl-b-Dglucosaminidase in adult patients with cystic fibrosis: Before, during and after treatment with intravenous antibiotics. J Cyst Fibros 2007; 6:67-73
33. Kang YH, Falk MC, Bentley TB, et al: Distri- bution and role of lipopolysaccharide in the pathogenesis of acute renal proximal tubule injury. Shock 1995; 4:441-449
34. Welles JS, Emmerson JL, Gibson WR, et al: Preclinical toxicology studies with tobramycin. Toxicol Appl Pharmacol 1973; 25: 398-409
35. Hottendorf GH, Barnett D, Gordon LL, et al: Nonparallel nephrotoxicity dose-response curves of aminoglycosides. Antimicrob Agents Chemother 1981; 19:1024-1028
36. Hardy ML, Hsu RC, Short CR: The nephrotoxic potential of gentamicin in the cat: Enzymuria and alterations in urine concentrating capability. J Vet Pharmacol Ther 1985; 8:382-392
37. Schwertz DW, Kreisberg JI, Venkatachalam MA: Gentamicin-induced alterations in pig kidney epithelial (LLC-PK1) cells in culture. J Pharmacol Exp Ther 1986; 236: 254-262
38. Swann JD, Ulrich R, Acosta D: Lack of changes in cytosolic ionized calcium in primary cultures of rat kidney cortical cells exposed to cytotoxic concentrations of gentamicin. Toxicol Appl Pharmacol 1990; 106:38-47
39. van der Harst MR, Bull S, Laffont CM, et al: Gentamicin nephrotoxicity-A comparison of in vitro findings with in vivo experiments in equines. Vet Res Commun 2005; 29: 247-261
40. Begg EJ, Barclay ML: Aminoglycosides-50 years on. Br J Clin Pharmacol 1995; 39: 597-603
41. Smith CR, Lipsky JJ, Laskin OL, et al: Double- blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 1980; 302: 1106-1109
42. Smyth A, Lewis S, Bertenshaw C, et al: Casecontrol study of acute renal failure in patients with cystic fibrosis in the UK. Thorax 2008; 63:532-535
43. Zucol F, Ammann RA, Berger C, et al: Realtime quantitative broad-range PCR assay for detection of the 16S rRNA gene followed by sequencing for species identification. J Clin Microbiol 2006; 44:2750-2759
44. Ostermann M, Chang RW: Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med 2007; 35:1837-1843; quiz 1852
45. Leibovici L, Paul M: Aminoglycoside/betalactam combinations in clinical practice. J Antimicrob Chemother 2007; 60:911-912
46. Freundlich M, Thomsen RW, Pedersen L, et al: Aminoglycoside treatment and mortality after bacteraemia in patients given appropriate empirical therapy: A Danish hospitalbased cohort study. J Antimicrob Chemother 2007; 60:1115-1123